ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Overview
The Anumana ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm is a software as a medical device (SaMD) designed to assist clinicians in identifying adult patients who may be at risk for Cardiac Amyloidosis (CA) using a standard 12-lead electrocardiogram (ECG).
- What it does:This AI-enabled algorithm analyzes ECG waveforms to detect patterns associated with CA that may not be apparent through human interpretation. It is intended to aid in earlier detection of CA in adults being evaluated for signs or symptoms consistent with the condition, including those with unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, or aortic stenosis.
- Who it is for:The tool is relevant for various specialties and care settings where patients are evaluated for cardiac symptoms, particularly those with comorbidities associated with CA. This includes cardiologists, primary care physicians, and other clinicians in hospital or outpatient settings.
- How it fits a clinical or practice workflow:The algorithm integrates into existing clinical workflows by utilizing standard 12-lead ECGs that are routinely obtained in practice, without requiring additional testing. It is not intended as a standalone diagnostic tool but rather to support clinicians in identifying patients who may benefit from further evaluation for CA.
- Notable capabilities:The ECG-AI CA algorithm was developed at Mayo Clinic and validated in a multi-center study.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-driven analysis of standard 12-lead ECGs
- Detects cardiac disease signals invisible to the human eye
- Integrates with existing clinical workflows and EHRs
- Aids in earlier detection of Cardiac Amyloidosis
- Software as a Medical Device (SaMD)
- Clinically validated with extensive evidence base
- Supports clinical decision-making at the point of care
- Eligible for reimbursement
Use Cases
- Early identification of cardiac amyloidosis in adults being evaluated for consistent signs or symptoms
- Screening patients with conditions commonly associated with cardiac amyloidosis (e.g., unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, aortic stenosis)
- Supporting clinicians in recognizing suspicion of cardiac amyloidosis from routine ECGs
- Guiding further clinical evaluation for at-risk patients
What Physicians Need to Know
This tool transforms standard 12-lead ECGs into a powerful tool for assessing cardiac conditions like Cardiac Amyloidosis. It integrates seamlessly into existing workflows and EHR systems, providing instant results to support ongoing patient care without requiring new systems or disruptions.
Anumana's platform is designed for seamless and secure integration directly within your EHR and on your own servers. It supports EHR configuration for orderables, results viewing, and HL7 data exchange. It also integrates with ECG Management Systems by processing digital waveform files (XML or DICOM) within the system framework, ensuring no PHI data is exported for external processing.
Details
| Category | Cardiology AI, Clinical Decision Support & Reference |
| Pricing | Unknown |
| Deployment | Integrated with existing ECG management systems and EHR environments |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Hospital Medicine, Internal Medicine |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Videos
Product demos, reviews, and walkthroughs for ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm.








